Show simple item record

dc.contributor.authorDehghan, R
dc.contributor.authorHosseinpour Feizi, MA
dc.contributor.authorPouladi, N
dc.contributor.authorBabaei, E
dc.contributor.authorMontazeri, V
dc.contributor.authorFakhrjoo, A
dc.contributor.authorSedaei, A
dc.contributor.authorAzarfam, P
dc.contributor.authorNemati, M
dc.date.accessioned2018-08-26T08:36:26Z
dc.date.available2018-08-26T08:36:26Z
dc.date.issued2015
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/52743
dc.description.abstractAssociation of P53 polymorphisms with the increased risk of various cancers has been investigated in numerous studies. However, the results were conflicting and no polymorphism has been determined as a definite risk factor. It is likely that the study of P53 combined genotypes and haplotypes may be more useful than individual polymorphisms. Thus, in this study, we analyzed the associations of intron 3 Ins16bp and exon 4 Arg72Pro polymorphisms, as well as their combined genotypes and haplotypes with the risk of differentiated thyroid carcinoma in Iranian-Azeri patients. This case-control study was performed on 84 Iranian Azeri patients with differentiated thyroid carcinoma and 150 healthy subjects. Intron 3 genotype was determined using PCR products analysis on polyacrylamide gels and AS-PCR was used for genotyping Arg72Pro polymorphism. The javastat online statistics package software and SHEsis program were applied for data analysis. There was no significant difference in genotype frequencies of both two polymorphisms between cases and controls. However, the (?16ins/?16ins) (Arg/Pro) genotype combination had a noticeable but not significant association with decreased risk of thyroid cancer development (OR = 0.497 95%CI: 0.209-1.168 P =0.080) and also the frequency of (?16ins-Pro) haplotype was significantly higher in controls rather than patients (OR = 0.543 95%CI: 0.326-0.903 P =0.018). In our study, there was association between (?16ins-Pro) haplotype with decreased risk of differentiated thyroid carcinoma development in Iranian-Azeri patients. é 2014, Ar?nyi Lajos Foundation.
dc.language.isoEnglish
dc.relation.ispartofPathology and Oncology Research
dc.subjectarginine
dc.subjectpolyacrylamide gel
dc.subjectproline
dc.subjectprotein p53
dc.subjectprotein p53
dc.subjectadult
dc.subjectArticle
dc.subjectAzeri (people)
dc.subjectcancer risk
dc.subjectcase control study
dc.subjectcontrolled study
dc.subjectdifferentiated thyroid cancer
dc.subjectexon
dc.subjectfemale
dc.subjectgene insertion
dc.subjectgenetic association
dc.subjectgenetic polymorphism
dc.subjectgenotype
dc.subjecthaplotype
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectintron
dc.subjectIranian people
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectoncocytoma
dc.subjectpolymerase chain reaction
dc.subjectthyroid carcinoma
dc.subjectthyroid follicular carcinoma
dc.subjecttumor suppressor gene
dc.subjectAdenocarcinoma, Follicular
dc.subjectcarcinoma
dc.subjectethnology
dc.subjectgenetic predisposition
dc.subjectgenetics
dc.subjecthaplotype
dc.subjectIran
dc.subjectmiddle aged
dc.subjectrisk factor
dc.subjectThyroid Neoplasms
dc.subjectAdenocarcinoma, Follicular
dc.subjectAdult
dc.subjectCarcinoma
dc.subjectCase-Control Studies
dc.subjectFemale
dc.subjectGenetic Predisposition to Disease
dc.subjectGenotype
dc.subjectHaplotypes
dc.subjectHumans
dc.subjectIran
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPolymorphism, Genetic
dc.subjectRisk Factors
dc.subjectThyroid Neoplasms
dc.subjectTumor Suppressor Protein p53
dc.titleAssociation of P53 (?16ins-Pro) Haplotype with the Decreased Risk of Differentiated Thyroid Carcinoma in Iranian-Azeri Patients
dc.typeArticle
dc.citation.volume21
dc.citation.issue2
dc.citation.spage449
dc.citation.epage454
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1007/s12253-014-9846-y


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record